Results 91 to 100 of about 7,079 (242)

Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes

Annals of Human Genetics, Volume 89, Issue 5, Page 398-405, September 2025.
ABSTRACT Pharmacogenomics, the use of germline genomic data to guide prescription to improve effective and safer medication, holds promise as a clinical intervention. To date in most health systems, there has been limited uptake of pharmacogenomic testing confined to a few single drug–gene associations.
John Henry McDermott, Videha Sharma, Jessica Keen, William Gerard Newman   +3 more
wiley   +1 more source

Scientometric mapping as a strategic intelligence tool for the governance of emerging technologies [PDF]

, 2014
How can scientometric mapping function as a tool of ’strategic intelligence’ to aid the governance of emerging technologies? The present paper aims to address this question by focusing on a set of recently developed scientometric techniques, namely ...
Hopkins, Michael, Leydersdorff, Loet, Rafols, Ismael, Rotolo, Daniele   +3 more
core   +2 more sources

Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource

Alimentary Pharmacology &Therapeutics, Volume 62, Issue 6, Page 630-645, September 2025.
Carriage of any loss of function NUDT15 varaint is associated with an increased risk of thiopurine‐induced myelosuppression. Pre‐treatment genotype testing of NUDT15. ABSTRACT Background The clinical utility and cost‐effectiveness of pre‐thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown.
Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, Neil Goodman, Mohmmed Sharip, Rebecca Smith, Maria Bishara, Claire Bewshea, Simeng Lin, Neil Chanchlani, Phoebe Hodges, Fakhirah Badrulhisham, Aamir Saifuddin, Sean Carlson, Andrea Centritto, Alexandra Marley, Muhammad Saad, Karishma Sethi‐Aora, Laura White, Alaa Abdelmeguid, Laetitia Pele, Shaji Sebastian, Christian Selinger, Peter Irving, Laura Fachal, Gareth Walker, Rachel Palmer, Nick Kennedy, Jayne Houghton, Mary Doona, Christopher Lamb, Chris Hyde, Miles Parkes, James Goodhand, Tariq Ahmad   +34 more
wiley   +1 more source

Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A/*3C Polymorphisms in a Patient with Pediatric Leukemia and the Effect of Steroid Therapy

Turkish Journal of Hematology, 2014
Myelosuppression is a serious complication during treatment of acute lymphoblastic leukemia and the duration of myelosuppression is affected by underlying bone marrow failure syndromes and drug pharmacogenetics caused by genetic polymorphisms.
Burcu Fatma Belen, Turkız  Gursel, Nalan Akyurek, Meryem Albayrak, Zühre  Kaya, Ülker  Kocak   +5 more
doaj   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 9, Page 1537-1566, September 2025.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. [PDF]

, 2012
The immunosuppressive drugs used to prevent the rejection of transplanted organs have a narrow therapeutic index. Under treatment results in episodes of rejection leading to either damage or loss of the organ. Over immunosuppression increases the risk of
Abboudi, H, Macphee, IA
core   +2 more sources

Pharmacogenomics in the UK National Health Service: Progress towards implementation

British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2241-2250, August 2025.
Over the past decade there has been considerable and growing enthusiasm about the promise of using genomics to inform healthcare. In particular, using genetic data to inform prescribing practice has emerged as a compelling policy priority for health systems around the world, not least in the NHS.
John H. McDermott, Maria Tsakiroglou, William G. Newman, Munir Pirmohamed   +3 more
wiley   +1 more source

Current Status of Autoimmune Hepatitis in Japan [PDF]

, 2008
Autoimmune hepatitis (AIH) is a chronic and progressive disease characterized by histological interface hepatitis, hypergammaglobulinemia, and circulating autoantibodies. Multiple factors, including molecular mimicry, a genetic background including major
Miyake, Yasuhiro, Yamamoto, Kazuhide
core   +1 more source

Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism. [PDF]

Basic Clin Pharmacol Toxicol, 2021
Zimdahl Kahlin A, Helander S, Wennerstrand P, Vikingsson S, Mårtensson LG, Appell ML.   +5 more
europepmc   +1 more source

Managing the innovation supply chain to maximize personalized medicine. [PDF]

, 2014
Personalized medicine epitomizes an evolving model of care tailored to the individual patient. This emerging paradigm harnesses radical technological advances to define each patient\u27s molecular characteristics and decipher his or her unique ...
Terzic, Andre, Waldman, Scott A
core   +2 more sources